title: NMDA receptor activation antagonizes the NMDA antagonist-induced antianxiety effect in the elevated plus-maze test in mice.
abstract: BACKGROUND
  The purpose of this study was to determine how the activation of different regulatory domains of the NMDA complex affects the antianxiety effect of antagonists acting at its distinct binding sites.
  
  
  METHODS
  The anxiolytic-like activity was assessed by the elevated plus-maze test in mice.
  
  
  RESULTS
  The anxiolytic activity of CGP 37849 (a competitive NMDA receptor antagonist) and L-701,324 (an antagonist at glycine site) was confirmed, but effects of both were significantly reduced by N-methyl-D-aspartic acid (NMDA) or by D-serine agonists at glutamate and glycine site of the NMDA receptor complex, respectively.
  
  
  CONCLUSIONS
  The obtained data suggest that stimulation of the glutamate or glycine recognition site of the NMDA receptor complex significantly decreases the antianxiety properties of antagonists of either site.
authors.affiliation: Department of Applied Pharmacy, Medical University of Lublin, Chodźki 1, PL 20-093 Lublin, Poland. ewa.poleszak@umlub.pl.
authors.forename: Ewa
authors.initials: E
authors.lastname: Poleszak
authors.forename: Anna
authors.initials: A
authors.lastname: Serefko
authors.forename: Aleksandra
authors.initials: A
authors.lastname: Szopa
authors.forename: Sylwia
authors.initials: S
authors.lastname: Wośko
authors.forename: Jarosław
authors.initials: J
authors.lastname: Dudka
authors.forename: Andrzej
authors.initials: A
authors.lastname: Wróbel
authors.forename: Tomasz
authors.initials: T
authors.lastname: Oniszczuk
authors.forename: Piotr
authors.initials: P
authors.lastname: Wlaź
mesh_terms: D015763:2-Amino-5-phosphonovalerate / Q000031:analogs & derivatives / Q000494:pharmacology; D000818:Animals; D014151:Anti-Anxiety Agents / Q000494:pharmacology*; D001007:Anxiety / Q000378:metabolism / Q000517:prevention & control* / Q000523:psychology; D001522:Behavior, Animal / Q000187:drug effects*; D001665:Binding Sites; D001921:Brain / Q000187:drug effects* / Q000378:metabolism; D004195:Disease Models, Animal; D004347:Drug Interactions; D018690:Excitatory Amino Acid Agonists / Q000494:pharmacology*; D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology*; D018698:Glutamic Acid / Q000378:metabolism; D005998:Glycine / Q000378:metabolism; D008024:Ligands; D008297:Male; D018782:Maze Learning / Q000187:drug effects*; D051379:Mice; D016202:N-Methylaspartate / Q000494:pharmacology; D015363:Quinolones / Q000494:pharmacology; D016194:Receptors, N-Methyl-D-Aspartate / Q000819:agonists* / Q000037:antagonists & inhibitors* / Q000378:metabolism; D012694:Serine / Q000378:metabolism
chemical_list: D014151:Anti-Anxiety Agents; D018690:Excitatory Amino Acid Agonists; D018691:Excitatory Amino Acid Antagonists; D008024:Ligands; D015363:Quinolones; D016194:Receptors, N-Methyl-D-Aspartate; C064539:2-amino-4-methyl-5-phosphono-3-pentenoic acid; D018698:Glutamic Acid; D012694:Serine; D016202:N-Methylaspartate; D015763:2-Amino-5-phosphonovalerate; C094635:L 701324; D005998:Glycine